Trial Profile
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 19 Jul 2019
Price :
$35
*
At a glance
- Drugs Tomivosertib (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Hodgkin's disease; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Effector Therapeutics
- 29 Nov 2018 Status changed from recruiting to discontinued.
- 08 Aug 2018 Planned End Date changed from 1 Jul 2019 to 1 Dec 2019.
- 08 Aug 2018 Planned primary completion date changed from 1 May 2019 to 1 Jun 2019.